Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.

17 Jun 2011

'Cell membrane capsules' made from real living cells improve functional drug delivery

The quest for better ways of encapsulating medicine so that it can reach diseased parts of the body has led scientists to harness - for the first time - living human cells to produce natural capsules with channels for releasing drugs and diagnostic agents.

16 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

15 Jun 2011

FDA extends Pacira's EXPAREL PDUFA goal date by three months

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for EXPAREL by three months.

14 Jun 2011

B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System

The U.S. Food and Drug Administration today approved B. Braun Medical Inc.'s application for 1g and 2g Ceftazidime for Injection USP and Dextrose Injection USP in the DUPLEX Drug Delivery System.

From B. Braun Melsungen AG 14 Jun 2011

Milestone completes $13 million round of equity financing

Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing.

13 Jun 2011

Mystic's key manufacturing technology for drug, biologic delivery systems receives U.S. patent

Mystic Pharmaceuticals, Inc. announces today that it has been granted U.S. Patent No. 7,963,089, "Deep Draw Container Forming Method," for a key manufacturing technology of its VersiDoser and VRx2 drug and biologic delivery systems.

13 Jun 2011

Moberg Derma receives EU/EEA CE mark approval for Kaprolac Skin Repair & Hydration

Moberg Derma AB announced that CE mark has been granted for Kaprolac Skin Repair & Hydration, a product designed to treat atopic eczema and dry skin. This CE mark provides authorization to market and sell the product in the EU/EEA.

10 Jun 2011

Self-assembling mini devices now enlisted in nanomedicine revolution

Measured in billionths of a meter, self-assembling nano-sized devices designed to carry drugs and imaging agents into the body are revolutionizing medicine by improving drug solubility and bio-distribution, providing a platform for combining targeting and imaging agents, and enabling membrane barriers to be crossed as well as making drug and imaging agent combination therapies possible.

8 Jun 2011

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Moberg Derma AB has entered into a distribution agreement with OzHealth Pharma for Emtrix - for discolored and damaged nails caused by nail fungus or nail psoriasis.

8 Jun 2011

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

MicroDose Therapeutx Inc. today announced that its collaborators at the University of Pittsburgh (Pitt) have completed a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).

8 Jun 2011

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher Pharmaceuticals Inc. today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.

8 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

Non-steroidal, oral contraceptive for men

Researchers at Columbia University Medical Center are honing in on the development of what may be the first non-steroidal, oral contraceptive for men. Tests of low doses of a compound that interferes with retinoic acid receptors (RARs), whose ligands are metabolites of dietary vitamin A, showed that it caused sterility in male mice.

7 Jun 2011

Drug Delivery News and Research

Further Reading

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

RHEI receives Chinese SFDA acceptance letter for MuGard

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

'Cell membrane capsules' made from real living cells improve functional drug delivery

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

FDA extends Pacira's EXPAREL PDUFA goal date by three months

B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System

Milestone completes $13 million round of equity financing

Mystic's key manufacturing technology for drug, biologic delivery systems receives U.S. patent

Moberg Derma receives EU/EEA CE mark approval for Kaprolac Skin Repair & Hydration

Self-assembling mini devices now enlisted in nanomedicine revolution

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Non-steroidal, oral contraceptive for men

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

3M introduces Kind Removal Silicone Tape for patients with sensitive, at-risk skin

Generex not to proceed with acquisition of interest in Global Medical Direct

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo